Tag: Celgene Corporation

August 1, 2017 Off

Celgene, Agios get FDA’s approval for AML treatment IDHIFA

By Dino Mustafić

Celgene Corporation  and Agios Pharmaceuticals, Inc. today announced that IDHIFA  was granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test.